20 results about "Mucosal inflammation" patented technology

The invention relates to an adipose-derived stem cell and exosome composition for mucosal inflammation and an application of the adipose-derived stem cell and exosome composition. The composition is composed of a hybrid nano-vesicle and a pulsatilla chinensis exosome compound in a mass ratio of 1: 1. The hybrid nanovesicles are prepared by fusing adipose-derived stem cell exosomes and lipidosome and modifying honey polysaccharide, and the pulsatilla chinensis exosome compound is loaded with interleukin 23 peptidomimetic, polyethylene glycol, black scale quantum dots and camptothecin. The composition has the functions of efficient anti-inflammation, immunoregulation, precise targeting and tissue repair, and meanwhile, the curative effect is enhanced through photo-thermal synergistic treatment. The preparation method comprises the steps of exosome extraction by a density gradient centrifugation method, liposome fusion and surface modification. The composition is suitable for treating mucosal inflammation such as inflammatory bowel disease and oral mucositis, has the advantages of high stability, good biocompatibility and the like, and provides a safe and effective novel treatment strategy for clinic.

An Olive Tree Polyphenol and Lactobacillus Reuteri Compound for Rebalancing Oral Inflammation and Dysbiosis Associated with Consumers who use Tobacco industry products such as nicotine pouches is disclosed. These tobacco products tend to have a propensity to facilitate the colonization of pathogens in oral biofilms leading to negative side effects such as oral mucosal inflammation and dysbiosis. An object of the invention is to develop a composition to mitigate oral inflammation and restore a normal oral, microbial balance. This mixture includes olive polyphenols and Lactobacillus Reuteri. The composition can also be manufactured into various embodiment forms, including but not limited to: an oral spray; an effervescent tablet; a chewable tablet; a capsule; and a powder. Two empirical research experiments were carried out to verify efficacy of the composition.

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

This invention discloses a traditional Chinese medicine composition for treating ulcerative colitis, its preparation method, combined drugs, and applications. The traditional Chinese medicine composition for treating ulcerative colitis of this invention is made from the following raw materials in parts by weight: Astragalus membranaceus 13-26 parts, Lonicera japonica 10-20 parts, Sargentodoxa cuneata 10-20 parts, Prunus mume 8-16 parts, Agrimonia pilosa 8-16 parts, Allium macrostemon 6-12 parts, Platycodon grandiflorus 6-12 parts, Coptis chinensis 3-6 parts, and Panax notoginseng powder 1-3 parts. An animal model of ulcerative colitis was constructed using DSS induction, and the results showed that the traditional Chinese medicine composition of this invention has a certain therapeutic effect on ulcerative colitis. Clinical studies showed that the traditional Chinese medicine composition of this invention, used in combination with mesalazine enteric-coated tablets, can reduce the modified Mayo score and serum inflammatory markers in patients with active ulcerative colitis, improve colonic mucosal inflammation and gastrointestinal symptoms, and effectively treat active ulcerative colitis of the damp-heat type.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The use of a probiotic, in particular an Enterococcus faecium strain named SF68, for the treatment of disorders characterized by alterations of the intestinal mucosa, particularly inflammations associated with altered intestinal permeability is described.

The present application belongs to the field of biological medicine and food technology, and particularly relates to application of milk-derived extracellular vesicles in improving brain health and / or improving nerve-related discomfort conditions. Compared with the prior art, the present application constructs a chronic restraint stress (CRS) induced anxiety model in adolescent mice, and uses open field test, buried bead test, tail suspension test and other behavioral experiments for functional evaluation. The results show that the milk-derived extracellular vesicles significantly improve the anxiety-like behavior of mice, indicating that the milk-derived extracellular vesicles can significantly improve the anxiety-like behavior of adolescent mice induced by chronic restraint stress (CRS) by remodeling the gut-brain axis function, and that the supplementation of milk-derived extracellular vesicles in adolescents can significantly reduce the susceptibility to anxiety in adulthood. At the same time, the present application also constructs a D-gal induced cognitive impairment model in mice, and the results show that it can reduce the production of pro-inflammatory cytokines, inhibit mucosal inflammation, thereby maintaining intestinal homeostasis and alleviating cognitive impairment.

Provided herein, inter alia, is a method for treating inflammatory dysfunction of the oral mucosa comprising topically administering an effective amount of resiniferatoxin (RTX).

The application discloses a kind of IgZ gene knockout zebrafish mucosal immunity antibody deletion model construction method and application, belong to genetic engineering technical field.The model construction method includes the following steps: S1, with the nucleotide sequence as shown in SEQ ID NO:1 as target point, using gene editing system to carry out IgZ gene knockout to zebrafish embryo, obtain IgZ gene knockout F0 generation mutant zebrafish;S2, F0 generation mutant zebrafish is self-crossed with the mutant zebrafish of target type same, sequencing obtains IgZ gene mutation F1 generation homozygote mutant zebrafish, it is IgZ gene knockout zebrafish mucosal immunity antibody deletion model.The zebrafish mucosal immunoglobulin synthesis disorder model is first constructed in the present application, and the model has good application value in the rapid screening and evaluation of drugs and natural efficacy factors with mucosal inflammation.

The invention discloses lactobacillus helveticus PP0208 and application thereof in prevention and treatment of allergic rhinitis, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide the lactobacillus helveticus for treating the allergic rhinitis, and the key point of the technical scheme is that the lactobacillus helveticus PP0208 is provided, and the preservation number of the lactobacillus helveticus PP0208 is CGMCC (China General Microbiological Culture Collection Center) No.28753. The lactobacillus helveticus PP0208 viable bacteria, the thermally inactivated bacteria and the extracellular vesicles of the lactobacillus helveticus PP0208 disclosed by the invention all have the effect of remarkably inhibiting allergic rhinitis mucosal inflammation, can down-regulate the expression of inflammatory factors and regulate the proportion of Treg cells, and cooperatively promotes the development of diseases towards the healing direction by coordinating the intestinal flora structure and the change of metabolites of the intestinal flora structure. The compound has a wide application prospect in preparation of drugs for effectively preventing and treating allergic rhinitis.

The present invention provides methods for treating mucosal inflammation or vascular leakage in a subject. The methods involve administering to the subject a pharmaceutical composition comprising RADA16 self-assembling peptide.

The invention discloses an oral cavity cleaning device for neurosurgical nursing, and particularly relates to the technical field of clinical nursing, a patient arm-chair is fixedly connected to the upper end of a supporting base, a nursing support is fixedly connected to the patient arm-chair, and a fixing bottom plate fixedly connected to the upper end of the supporting base is arranged below the patient arm-chair; and a spray gun is arranged on the fixed bottom plate. According to the oral cavity cleaning device for neurosurgery nursing, through the synergistic effect of the switching assembly and the driving assembly, mechanical switching of three core functions of water spraying cleaning, air injection drying and air suction pollution discharge is achieved, in the water spraying mode, high-pressure clear water can be used for flushing residues in hidden areas such as tooth slits and tongue coating, and the cleaning effect is good. The air injection mode can quickly blow-dry oral effusion and reduce mucosa inflammation caused by a humid environment, the air suction mode can efficiently remove residual effusion and falling residues in the oral cavity through negative pressure adsorption of an air pump, and the problems that a traditional tool is not thorough in cleaning and needs to frequently replace equipment are solved.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

The invention discloses sound power driven Janus hydrogel as well as a preparation method and application thereof. The hydrogel comprises silver peroxide and a hydrogel matrix, the hydrogel matrix is prepared from methacrylated silk fibroin, gamma-polyglutamic acid-N-hydroxysuccinimide ester and a photoinitiator. Through component synergy and structural innovation, the prepared hydrogel can release ROS according to ultrasonic drive, destroys bacterial biofilms, and cooperates with Ag < + > slowly released by Ag2O2 to achieve an efficient sterilization effect; after the hydrogel is cross-linked by ultraviolet light, a Janus structure of which one side is adhered and the other side is anti-adhesion can be formed. Pharmacodynamic experiment results show that the sonodynamic-driven Janus hydrogel prepared by the invention has an excellent antibacterial effect, can be used for promoting wound healing, repairing alveolar bone defects and the like, and also provides a new choice for repairing infections such as periodontitis, oral mucosa inflammation and the like or skin wounds.

The invention belongs to the technical field of biological medicine and food, and particularly relates to application of milk-derived extracellular vesicles to improvement of brain health conditions and / or improvement of nerve-related discomfort conditions. Compared with the prior art, a chronic constraint stress (CRS)-induced puberty mouse anxiety model is constructed, functional evaluation is performed by behavioral experiments such as an open field experiment, a bead embedding experiment and a tail suspension experiment, and results show that the milk-derived extracellular vesicles remarkably improve mouse anxiety-like behaviors; it is shown that the milk-derived extracellular vesicles can significantly improve the chronic bound stress (CRS) induced adolescent mouse anxiety-like behavior by reshaping the intestinal-brain axis function, and the anxiety susceptibility of adolescents can be significantly reduced by supplementing the milk-derived extracellular vesicles to teenagers; meanwhile, a D-gal induced mouse cognitive impairment model is constructed, and the result shows that mucosa inflammation can be inhibited by reducing generation of proinflammatory cytokines, so that intestinal homeostasis is maintained, and cognitive impairment is relieved.

The invention belongs to the technical field of biomedicine, and particularly relates to application of a cocklebur fruit plant exosome to treatment of allergic rhinitis, the cocklebur fruit plant exosome has a definite treatment effect on the allergic rhinitis, can improve allergic behaviors, relieve respiratory mucosa inflammation and down-regulate expression of allergy-related molecules (IgE, IL-4 and histamine), and can be used for treating allergic rhinitis. The anti-inflammatory and anti-allergic active ingredients of the fructus xanthii are naturally enriched, so that the bioavailability of the active ingredients is remarkably improved; the therapeutic effects of inhibiting histamine release, regulating immune balance and relieving nasal mucosa inflammation infiltration are achieved by relying on the carried natural active substances; meanwhile, by virtue of inherent low immunogenicity and high biocompatibility of the plant exosome, the safety concern of a traditional Chinese medicine preparation is avoided, and the medication safety is remarkably improved.

The invention discloses an application of high-oxygen water and Wuji decoction in a medicine for treating helicobacter pylori infectious gastrointestinal diseases, and relates to the technical field of biological medicine, research finds that the high-oxygen water and Wuji decoction have a remarkable effect in treating the helicobacter pylori infectious gastrointestinal diseases, and particularly, the high-oxygen Wuji decoction has a remarkable effect in treating the helicobacter pylori infectious gastrointestinal diseases by inhibiting an S100A8 / S100A9-TLR4-p38 signal channel. The expression of S100A8, S100A9, TLR4 and p38 is down-regulated, the generation of inflammatory factors IL-8 and TNF-alpha is inhibited, and the inflammatory response of gastric mucosa is relieved; meanwhile, by regulating and controlling an HSP70 / NF-kappa B signal channel, the expression of HSP70 is up-regulated, the expression of NF-kappa B is reduced, and the inflammatory response of gastric mucosa is relieved; finally, the high-oxygen Wuji decoction improves the expression level of SIgA and protects intestinal barriers; the ratio of the phylum firmicalis to the phylum bacteroides is recovered, the richness of intestinal flora species is improved, and the structure of the intestinal flora is adjusted.

Hyperbranched dextrins, preferentially hyperbranched and hydrogenated dextrins, for topical use in the prevention or treatment of at least one symptom selected from redness, heat, swelling and pain, as well as in the prevention or treatment of the symptoms of skin inflammation and of mucosal inflammation. The invention also relates to the use of these hyperbranched, and preferably hyperbranched and hydrogenated, dextrins to prevent or reduce or eliminate the irritant effect induced by ingredients contained in cosmetic or dermatological compositions.

The utility model relates to the technical field of oncology department radiation, in particular to a protection device for radiotherapy, which comprises two bottom plates and a plurality of groups of radiation instruments, the plurality of groups of radiation instruments are all arranged above the bottom plates, two support frames are fixedly connected between the tops of the two bottom plates, a first screw rod is rotatably connected between the two support frames, and a second screw rod is rotatably connected between the two support frames. The outer portion of the first lead screw is in threaded connection with a connecting block, the bottom of the connecting block is fixedly connected with a first protection plate, the bottom of the inner wall of one supporting frame is fixedly connected with a second protection plate, and rotary hinges are fixedly connected to the two sides between the first protection plate and the second protection plate. The beneficial effects of the utility model lie in that radiation therapy can cause skin erythema, ulcer and mucosa inflammation, these side effects not only affect the living quality of a patient, but also increase the disruption rate of the therapy, and through effective protection, the radiation dose of these parts can be reduced, the side effects can be reduced or avoided, and the treatment effect can be improved. Compared with a traditional device, the operation quality and the use efficiency are greatly improved.

The present disclosure relates to 1,4:3,6-dianhydrohexitol, specifically isosorbide, and compositions comprising 1,4:3,6-dianhydrohexitol for treating oral inflammatory conditions. These conditions, which include both oral mucosal inflammation and periodontal diseases, are characterized by elevated levels of pro-inflammatory mediators, particularly IL-1 alpha and IL-8. Using the EpiOral™ model, isosorbide has demonstrated significant ability to reduce IL-1 alpha secretion and IL-8 gene expression in inflamed oral epithelial cells. These results support its therapeutic relevance in treating oral inflammatory conditions through modulation of key inflammatory mediators.